We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Pfizer, BHP, Facebook, Tesla and Humana
Read MoreHide Full Article
For Immediate Release
Chicago, IL –July 5, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Pfizer (PFE - Free Report) , BHP Billiton (BHP - Free Report) , Facebook , Tesla (TSLA - Free Report) and Humana (HUM - Free Report) .
Here are highlights from Tuesday’s Analyst Blog:
Top Analyst Reports for Pfizer, BHP Billiton and Facebook
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Pfizer, BHP Billiton and Facebook. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Buy-ranked Pfizer’s shares have outperformed the peer group year-to-date (the stock is up +0.3% over this period vs. a -5.1% decline for the Zacks Large-Cap Pharmaceuticals industry). Pfizer has been working on strengthening its product portfolio through acquisitions and licensing deals. However, Pfizer is facing headwinds in the form of genericization of key drugs, supply challenges in the legacy Hospira portfolio, pricing pressure and rising competition, which are hurting the top line.
Nonetheless, the Zacks analyst believes that new products like Ibrance, contribution from acquisitions, cost-cutting efforts, a lower tax rate and share buybacks should help the company achieve its guidance. Pfizer also boasts a strong pipeline and expects approximately 25 to 30 drug approvals through 2022, including around 15 products that have blockbuster potential. Pfizer’s growing immuno-oncology portfolio offers a strong potential. Bavencio is being considered a key long-term growth driver for Pfizer.
Shares of buy-rated BHP Billiton’s shares have outperformed the Zacks Mining-Miscellaneous industry over the past year (+34.2% vs. +23.1%). BHP Billiton is gaining competency on the back of sturdier productivity and remains on track to deleverage balance sheet over time. BHP Billiton expects capital and exploration costs to be lower than $8 billion by fiscal 2020-end. It is making its operations more efficient on the back of smarter technology adoption across the entire value chain.
BHP Billiton expects to secure productivity gains of $2 billion by fiscal 2019-end. The company's board recently approved a capital investment of $2.9 billion in the South Flank project in central Pilbara, Western Australia, adding a major project to its portfolio.
BHP Billiton remains focused on providing increased returns to shareholders. Also, the Zacks Consensus Estimate for the stock have been revised upward for both fiscal 2018 and fiscal 2019, over the last 30 days.
Buy-ranked Facebook’s shares have outperformed the S&P 500 index so far this year, gaining +11.9% vs. +2.3%. Facebook is benefitting from robust growth in advertising and user base. Facebook’s user base of 2.2 billion coupled with Instagram’s 1 billion users provides a huge canvas for advertisers, which, in turn, is driving the top line of the company. Rising mobile conversions on the platform is boosting mobile ad growth.
Growing popularity of Stories across all its major platforms, with Instagram taking center stage, is a tailwind. Apart from mobile and video, the monetization opportunities of Messenger, WhatsApp and Oculus and a huge user base are expected to drive growth going ahead. Facebook has a strong balance sheet and generates significant cash flow, which makes it an attractive stock for investors.
Other noteworthy reports we are featuring today include Tesla and Humana.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Pfizer, BHP, Facebook, Tesla and Humana
For Immediate Release
Chicago, IL –July 5, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Pfizer (PFE - Free Report) , BHP Billiton (BHP - Free Report) , Facebook , Tesla (TSLA - Free Report) and Humana (HUM - Free Report) .
Here are highlights from Tuesday’s Analyst Blog:
Top Analyst Reports for Pfizer, BHP Billiton and Facebook
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Pfizer, BHP Billiton and Facebook. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Buy-ranked Pfizer’s shares have outperformed the peer group year-to-date (the stock is up +0.3% over this period vs. a -5.1% decline for the Zacks Large-Cap Pharmaceuticals industry). Pfizer has been working on strengthening its product portfolio through acquisitions and licensing deals. However, Pfizer is facing headwinds in the form of genericization of key drugs, supply challenges in the legacy Hospira portfolio, pricing pressure and rising competition, which are hurting the top line.
Nonetheless, the Zacks analyst believes that new products like Ibrance, contribution from acquisitions, cost-cutting efforts, a lower tax rate and share buybacks should help the company achieve its guidance. Pfizer also boasts a strong pipeline and expects approximately 25 to 30 drug approvals through 2022, including around 15 products that have blockbuster potential. Pfizer’s growing immuno-oncology portfolio offers a strong potential. Bavencio is being considered a key long-term growth driver for Pfizer.
Shares of buy-rated BHP Billiton’s shares have outperformed the Zacks Mining-Miscellaneous industry over the past year (+34.2% vs. +23.1%). BHP Billiton is gaining competency on the back of sturdier productivity and remains on track to deleverage balance sheet over time. BHP Billiton expects capital and exploration costs to be lower than $8 billion by fiscal 2020-end. It is making its operations more efficient on the back of smarter technology adoption across the entire value chain.
BHP Billiton expects to secure productivity gains of $2 billion by fiscal 2019-end. The company's board recently approved a capital investment of $2.9 billion in the South Flank project in central Pilbara, Western Australia, adding a major project to its portfolio.
BHP Billiton remains focused on providing increased returns to shareholders. Also, the Zacks Consensus Estimate for the stock have been revised upward for both fiscal 2018 and fiscal 2019, over the last 30 days.
Buy-ranked Facebook’s shares have outperformed the S&P 500 index so far this year, gaining +11.9% vs. +2.3%. Facebook is benefitting from robust growth in advertising and user base. Facebook’s user base of 2.2 billion coupled with Instagram’s 1 billion users provides a huge canvas for advertisers, which, in turn, is driving the top line of the company. Rising mobile conversions on the platform is boosting mobile ad growth.
Growing popularity of Stories across all its major platforms, with Instagram taking center stage, is a tailwind. Apart from mobile and video, the monetization opportunities of Messenger, WhatsApp and Oculus and a huge user base are expected to drive growth going ahead. Facebook has a strong balance sheet and generates significant cash flow, which makes it an attractive stock for investors.
Other noteworthy reports we are featuring today include Tesla and Humana.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.